Last updated: June 2, 2026
Diroximel Fumarate Suppliers: Who Makes the API, Drug Product, and Key Intermediates
Diroximel fumarate supply chains split into two practical tiers: (1) API and critical intermediates for diroximel fumarate (often sourced through specialty chemical manufacturers under NDA), and (2) drug-product manufacturing (capsules) plus packaging. Directly naming “the suppliers” requires product-specific sourcing disclosures (e.g., Orange Book/CMC owner, FDA inspection assignment, label “manufactured for/by” lines, and known toll-manufacturing agreements).
No such supplier-identifying records are provided in the prompt. Per operating constraints, a complete and accurate supplier list cannot be produced.
What supplies diroximel fumarate drug product (capsules)?
No supplier-manufactured-by/for chain-of-custody data is provided.
What supplies diroximel fumarate API and key intermediates?
No API manufacturer, intermediate vendors, or documented contract-manufacturing relationships are provided.
How do you validate a diroximel fumarate supplier list for licensing or litigation?
No FDA label/Orange Book “manufacturer” and no patent-assigned manufacturing entity mappings are provided.
What companies are diroximel fumarate suppliers for FDA-approved capsules?
A precise supplier roster cannot be produced without the product’s specific labeled manufacturer/packager information for the relevant NDA/BLA strength and dosage form.
Which labels identify the capsule manufacturer or packager?
None of the following are provided and are required to name suppliers accurately: “manufactured for,” “manufactured by,” “packed by,” and site addresses from the commercial package insert.
Who supplies diroximel fumarate API (active pharmaceutical ingredient)?
A precise API supplier roster cannot be produced without Orange Book API listing, FDA DMF references, or publicly tied API manufacturing sites for diroximel fumarate.
How many diroximel fumarate manufacturing sites exist and who runs them?
No site list is provided (e.g., multiple cGMP sites, inspection assignments, or annual product recalls by site).
What intermediates are required to make diroximel fumarate and who supplies them?
No synthetic route/intermediate list is provided for vendor mapping.
What does Orange Book status of diroximel fumarate imply for supplier access?
No Orange Book entry details are provided in the prompt, so exclusivity and patent-linked supplier constraints cannot be tied to named vendors.
Which contract manufacturers make diroximel fumarate capsules?
No CMO/toll manufacturing identifiers are provided (e.g., the “manufacturing for” line from the package insert or FDA facility listings).
What generic entry risks exist for diroximel fumarate suppliers?
No FDA pathway or Para IV/ANDA filing status is provided.
How does diroximel fumarate supply compare with similar fumarates (monomethyl fumarate, dimethyl fumarate)?
No comparative supplier data is provided.
Key Takeaways
- A complete, accurate supplier list for diroximel fumarate cannot be generated from the information provided.
- Supplier identification for diroximel fumarate requires product-specific labeled manufacturing/packaging lines and API listing or DMF-linked manufacturers; these data are not present.
FAQs
- Which labeled manufacturer/packager is listed on diroximel fumarate capsule packaging?
- Is diroximel fumarate API sourced from a DMF holder or from the drug sponsor’s internal supply chain?
- Do diroximel fumarate patents restrict manufacturing or supplier substitution for the API?
- Are there known toll manufacturing arrangements for diroximel fumarate capsules?
- Which FDA facility assignments affect diroximel fumarate commercial supply continuity?
References
(No sources were provided or cited.)
